Karuna Therapeutics Management

Management criteria checks 1/4

Karuna Therapeutics' CEO is Bill Meury, appointed in Jan 2023, has a tenure of 1.17 years. directly owns 0.027% of the company’s shares, worth $3.41M. The average tenure of the management team and the board of directors is 1.1 years and 4.3 years respectively.

Key information

Bill Meury

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.2yrs
CEO ownership	0.03%
Management average tenure	1.1yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO

Bill Meury (55 yo)

1.2yrs

Tenure

Mr. William Meury, also known as Bill, served as a Partner at Hildred Capital Management LLC. He serves as Director at Crown Laboratories Inc and serves as its Chairman of the Board of Directors. He curren...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andrew Miller	Founder and President of Research & Development	no data	US$5.77m	0.037% $ 4.6m
Stephen Brannan	Chief Medical Officer	7yrs	US$4.41m	0.095% $ 11.9m
William Meury	President	1.2yrs	no data	0.027% $ 3.4m
Jason Brown	Chief Financial Officer	less than a year	no data	0.037% $ 4.6m
Alexis Smith	Vice President of Corporate Affairs & Investor Relations	no data	no data	no data
Mia Kelley	General Counsel	4.2yrs	no data	no data
Frank Truslow	Senior Vice President of Corporate Development	less than a year	no data	no data
Jonathan Rosin	Chief Human Resources Officer	less than a year	no data	no data
Alan Breier	Chair of Scientific Advisory Board & Chief Clinical Advisor	no data	no data	no data
Ronald Marcus	Senior Vice President of Medical	3.2yrs	no data	no data
William Kane	Chief Commercial Officer	1.1yrs	no data	0.013% $ 1.6m

1.1yrs

Average Tenure

57.5yo

Average Age

Experienced Management: KRTX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
William Meury	President	1.2yrs	no data	0.027% $ 3.4m
Alan Breier	Chair of Scientific Advisory Board & Chief Clinical Advisor	no data	no data	no data
James Healy	Independent Director	4.8yrs	US$336.10k	0.085% $ 10.7m
Jeffrey Jonas	Director	5.4yrs	US$326.60k	0% $ 0
Edmund Harrigan	Member of Scientific Advisory Board	3.3yrs	US$701.26k	no data
Christopher Coughlin	Chairman	3.9yrs	US$373.15k	0% $ 0
Steven Paul	Director & Member of Scientific Advisory Board	6yrs	US$11.22m	0.37% $ 47.0m
Allan Levey	Member of Scientific Advisory Board	no data	no data	no data
Atul Pande	Independent Director & Member of Scientific Advisory Board	4.8yrs	US$344.60k	0% $ 0
William Potter	Member of Scientific Advisory Board	no data	no data	no data
Laurie Olson	Independent Director	3.6yrs	US$345.10k	0% $ 0
Richard Keefe	Member of Scientific Advisory Board	no data	no data	no data

4.3yrs

Average Tenure

69yo

Average Age

Experienced Board: KRTX's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/03/18 11:20
End of Day Share Price	2024/03/15 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Karuna Therapeutics, Inc. is covered by 20 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Caroline Palomeque	Berenberg
Esther Lannie Hong	Berenberg
Jason Matthew Gerberry	BofA Global Research

Karuna Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Chief Medical Officer notifies of intention to sell stock

Board Member exercised options to buy US$9.9m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Recent updates

Karuna Therapeutics, Inc. Files Form 15

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Board Member exercised options to buy US$9.9m worth of stock.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Karuna Therapeutics: Getting Sold Short

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.2% to US$327

Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 23%

Consensus revenue estimates decrease by 22%

Price target increased by 9.9% to US$291

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Karuna Therapeutics, Inc. Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

New minor risk - Profitability

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for Karxt for the Treatment of Schizophrenia

Karuna Therapeutics, Inc. Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates decrease by 55%

New minor risk - Profitability

Third quarter 2023 earnings released: US$3.16 loss per share (vs US$2.38 loss in 3Q 2022)

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

Karuna Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics, Inc. Submits New Drug Application to U.S. Food and Drug Administration for Karxt for the Treatment of Schizophrenia

Director exercised options and sold US$2.5m worth of stock

New minor risk - Profitability

Karuna Therapeutics, Inc. Announces Chief Financial Officer Changes

Director exercised options and sold US$2.6m worth of stock

Karuna Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Director notifies of intention to sell stock

CFO & Secretary notifies of intention to sell stock

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting

Consensus revenue estimates increase by 20%

Co-Founder & COO notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Independent Director exercised options and sold US$96k worth of stock

Chief Medical Officer exercised options and sold US$920k worth of stock

Consensus revenue estimates fall by 85%

CFO & Secretary notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

Independent Director exercised options and sold US$113k worth of stock

CFO & Secretary exercised options to buy US$2.3m worth of stock.

Chief Medical Officer exercised options and sold US$965k worth of stock

Karuna Therapeutics, Inc. Announces Executive Changes, Effective January 3, 2023

Co-Founder & COO exercised options and sold US$168k worth of stock

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates fall by 25%

Co-Founder & COO exercised options and sold US$444k worth of stock

Chief Medical Officer exercised options and sold US$992k worth of stock

CFO & Secretary notifies of intention to sell stock

CFO & Secretary recently sold US$3.4m worth of stock

Chief Medical Officer exercised options and sold US$1.2m worth of stock

Karuna Therapeutics: This Ship Has Sailed

Consensus forecasts updated

Price target increased to US$236

Karuna Therapeutics, Inc. Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

High number of new directors

Chief Medical Officer exercised options and sold US$1.9m worth of stock

Karuna Therapeutics: Front-Running KarXT Phase 3

Chief Medical Officer exercised options and sold US$509k worth of stock

Independent Director notifies of intention to sell stock